A Phase 3 interventional study of Maxigesic 325 and Acetaminophen in Dental Pain, sponsored by AFT Pharmaceuticals, Ltd.. Completed at 4 sites in 2 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2018-12-06.
Sponsored by AFT Pharmaceuticals, Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine whether the analgesic effects of Maxigesic USA are greater than acetaminophen, ibuprofen or placebo.
The combination of 500mg acetaminophen and 150mg ibuprofen has been shown to improve analgesia compared with the individual components, when given as 2 tablets (i.e. total of 1,000/300 mg) 4 times a day.
Recent concerns over the safety of acetaminophen have led to some regulatory agencies restricting the maximum dose of acetaminophen per tablet to 325 mg, while maintaining the maximum daily dose of 4000mg per day.
A dosing regimen of three tablets of Maxigesic 325 four times a day gives a total daily dose of 3900mg acetaminophen and 1170mg ibuprofen.
The primary objective of the study is to compare time-adjusted SPID of the VAS pain intensity scores up to 48 hours after the first dose of study medication among the four study groups.
Secondary objectives are:
To compare the time to onset of pain relief after the first dose of study drug defined as (i) perceptible and (ii) meaningful pain relief among the four study groups using the two stopwatch method.
To compare the maximum VAS pain scores up to 48 hours after the first dose of study medication among the four study groups.
To compare the response rates (response rate to be defined as the percentage of participants who reduce their pain intensity scores by at least 50% compared with the baseline VAS measure) among the four study groups.
To compare the time to peak reduction in VAS pain intensity scores following the first dose of study medication among the four study groups.
To compare the time to requirement for rescue medication among the four study groups.
To compare the percentage of participants who use rescue medication among the four study groups.
To compare the amount of rescue medication used (defined as number of tablets) among the four study groups.
To compare the categorical global pain rating among the four study groups.
Safety:
To compare adverse event rates for the 48-hour study period and up to Day 30 among the four treatment groups.
To compare the incidence of known specific NSAID and paracetamol side effects (e.g. GI ulceration or bleeding, indigestion/stomach pain, post-operative bleeding, bronchospasm, skin rashes, water retention, renal failure, thromboembolic events and evidence of clinical hepatitis) during the 48-hour study period and up to Day 30 among the four study groups.
Planned hospital admissions and/or surgical operations for an illness or disease which existed before the study drug was given or the participant was randomized in the study will not be considered adverse events.
143 studies on the registry are indexed under Toothache; 28 are open to participants now.
This study's enrollment of 408 is above the median of 84 across 123 interventional studies indexed under Toothache.
Browse Toothache studies →AFT Pharmaceuticals, Ltd. is the lead sponsor of 9 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Acetaminophen 325mg + ibuprofen 97.5mg per tablet, two tablets every 6 hours, orally
Drug: Maxigesic 325
Acetaminophen 325mg per tablet (standard dose acetaminophen), two tablets every 6 hours, orally
Drug: Acetaminophen
Ibuprofen 97.5mg per tablet (i.e. low dose ibuprofen), two tablets every 6 hours, orally
Drug: Ibuprofen
Placebo tablets, every 6 hours, orally
Drug: Placebo
Drug pages: Acetaminophen · Ibuprofen
Maxigesic USA (acetaminophen 325 mg + ibuprofen 97.5mg), three tablets four times a day with food for 48 hours
Also known as: Maxigesic
Acetaminophen 325 mg, 3 tablets four times a day, with food for 48 hours
Also known as: paracetamol
Ibuprofen 97.5mg, three tablets four times a day, with food for 48 hours.
placebo, three tablets four times a day, with food for 48 hours
SPID (Summed Pain Intensity Differences)
The time-adjusted Summed Pain Intensity Differences (SPIDs) of the VAS pain intensity scores up to 48 hours after the first dose of study medication. This was calculated from the visual analogue scale (VAS) pain intensity scores recorded during the 48 hours double blind treatment period, with the last measure taken just prior to the final dose of blinded study medication. The visual analogue scale is 100mm long with 0= no pain and 100=worst pain imaginable. The Visual Analogue Scale It is expected that treatments which can provide superior analgesic effect will demonstrate a greater Summed Pain Intensity Difference.
Time frame: 48 hours afte the first dose
455 Subjects have been consented and screened, out of which 47 subjects were screening failures and did not receive the first dose of study medication. Among 408 subjects, 273 subjects enrolled from New Zealand sites and 135 subjects enrolled from USA site from May 2013 to Jan 2015.
| Milestone | Maxigesic 325 | Acetaminophen | Ibuprofen | Placebo |
|---|---|---|---|---|
| Started | 110 | 111 | 112 | 75 |
| Completed | 107 | 108 | 108 | 68 |
| Not completed | 3 | 3 | 4 | 7 |
The time-adjusted Summed Pain Intensity Differences (SPIDs) of the VAS pain intensity scores up to 48 hours after the first dose of study medication. This was calculated from the visual analogue scale (VAS) pain intensity scores recorded during the 48 hours double blind treatment period, with the last measure taken just prior to the final dose of blinded study medication. The visual analogue scale is 100mm long with 0= no pain and 100=worst pain imaginable. The Visual Analogue Scale It is expected that treatments which can provide superior analgesic effect will demonstrate a greater Summed Pain Intensity Difference.
| score on a scale | Maxigesic 325 | Acetaminophen | Ibuprofen | Placebo |
|---|---|---|---|---|
| SPID (Summed Pain Intensity Differences) | 31.56 ± 1.94 | 17.71 ± 1.89 | 23.18 ± 1.89 | 14.86 ± 2.26 |
Collected over Treatment-emergent Adverse Events were collected from the randomization to the follow up telephone contact made at 30 days after the surgery (Surgery Day is Day 1). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Maxigesic 325 | 1/110 (0.9%) | 1/110 (0.9%) | 41/110 (37.3%) |
| Acetaminophen | 0/111 (0%) | 0/111 (0%) | 54/111 (48.6%) |
| Ibuprofen | 0/112 (0%) | 0/112 (0%) | 40/112 (35.7%) |
| Placebo | 0/75 (0%) | 0/75 (0%) | 38/75 (50.7%) |
| Event | Maxigesic 325 | Acetaminophen | Ibuprofen | Placebo |
|---|---|---|---|---|
| Death due gun shotInjury, poisoning and procedural complications | 1/110 | 0/111 | 0/112 | 0/75 |
| Event | Maxigesic 325 | Acetaminophen | Ibuprofen | Placebo |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 15/110 | 19/111 | 15/112 | 17/75 |
| VomitingGastrointestinal disorders | 9/110 | 14/111 | 5/112 | 7/75 |
| HeadacheNervous system disorders | 8/110 | 9/111 | 9/112 | 7/75 |
| Facial swellingSkin and subcutaneous tissue disorders | 6/110 | 10/111 | 8/112 | 5/75 |
| DizinessNervous system disorders | 4/110 | 5/111 | 3/112 | 5/75 |
| Age, Continuous(years) | Maxigesic 325 | Acetaminophen | Ibuprofen | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 25.4 ± 7.0 | 25.0 ± 6.9 | 24.3 ± 5.9 | 24.3 ± 6.3 | 24.8 ± 6.6 |
| Sex: Female, Male(Participants) | Maxigesic 325 | Acetaminophen | Ibuprofen | Placebo | Total |
|---|---|---|---|---|---|
| Female | 69 | 76 | 82 | 48 | 275 |
| Male | 41 | 35 | 30 | 27 | 133 |
| Region of Enrollment(participants) | Maxigesic 325 | Acetaminophen | Ibuprofen | Placebo | Total |
|---|---|---|---|---|---|
| New Zealand | 73 | 75 | 75 | 50 | 273 |
| United States | 37 | 36 | 37 | 25 | 135 |
The record gives a start of Apr 2013, a primary completion of Dec 2014 and a completion of Jan 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2018, 4 years after primary completion. A results delay was requested in Feb 2016.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Acetaminophen · Ibuprofen
AFT Pharmaceuticals, Ltd.